Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST).

[1]  F. Harrell,et al.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). , 1997, American heart journal.

[2]  A. Skene,et al.  Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure , 1997, The Lancet.

[3]  R. Virmani,et al.  Apoptosis in myocytes in end-stage heart failure. , 1996, The New England journal of medicine.

[4]  P. Denes,et al.  Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure. , 1996, American heart journal.

[5]  S. Yusuf,et al.  Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: Results of the studies of left ventricular dysfunctions (SOLVD) registry , 1993 .

[6]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[7]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[8]  M. Demedts,et al.  Intermittent dobutamine infusion in severe chronic heart failure in elderly patients. , 1990, Gerontology.

[9]  L. Miller,et al.  Outpatient dobutamine for end‐stage congestive heart failure , 1990, Critical care medicine.

[10]  S. Gottlieb,et al.  Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. , 1989, Journal of the American College of Cardiology.

[11]  R. Cody.  Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? I. Introduction. , 1988, Journal of the American College of Cardiology.

[12]  N. Zafrir,et al.  Short‐ and long‐term dobutamine treatment in chronic ischemic heart failure , 1987, Clinical cardiology.

[13]  B. Pitt,et al.  Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. , 1986, American heart journal.

[14]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[15]  C. Liang,et al.  Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine. , 1984, Circulation.

[16]  P. Poole‐Wilson,et al.  Symptoms, haemodynamics, and exercise capacity during long term treatment of chronic heart failure. Experience with pirbuterol. , 1983, British heart journal.

[17]  R. Magorien,et al.  The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy. , 1983, American heart journal.

[18]  E. Sonnenblick,et al.  Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure. , 1983, The American journal of cardiology.

[19]  R. Magorien,et al.  Long-term benefit of dobutamine in patients with congestive cardiomyopathy. , 1980, American heart journal.